Utkarsh Chauhan

Mr. Utkarsh Chauhan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AGAnukul Ghimire
Anukul Ghimire
JPJaye Platnich
Jaye Platnich
UCUtkarsh Chauhan
Utkarsh Chauhan
Warm autoimmune hemolytic anemia (AIHA) is a rare complication of COVID-19 infection. We report a case of warm AIHA in a patient with COVID-19 pneumonia treated with methylprednisolone and several red blood cell transfusions. Despite treatment of the warm AIHA, the patient’s reticulocyte count remained low, and his biochemical markers were suggestive of pure red cell aplasia, which was later attributed to a concurrent parvovirus B19 infection. This case highlights an unusual situation of two separate hematological processes caused by two separate and simultaneous viral infections.

7 October 2023 in BioMedInformatics
Verified
Journal Article
Open access
PDF file
UCUtkarsh Chauhan
Utkarsh Chauhan
KZKaiqiong Zhao
Kaiqiong Zhao
JWJohn W. Walker
John W. Walker
JMJohn Robert Mackey
John Robert Mackey
The Kaplan–Meier (KM) estimator is widely used in medical research to estimate the survival function from lifetime data. KM estimation is a powerful tool to evaluate clinical trials due to simple computational requirements, its use of a logrank hypothesis test, and the ability to censor patients. However, KM estimation has several constraints and fails to generalize to ordinal variables of clinical interest, such as toxicity and ECOG performance. We devised weighted trajectory analysis (WTA) to combine the advantages of KM estimation with the ability to visualize and compare treatment groups for ordinal variables and fluctuating outcomes. To assess statistical significance, we developed a new hypothesis test analogous to the logrank test. We demonstrated the functionality of WTA through 1000-fold clinical trial simulations of unique stochastic models of chemotherapy toxicity and schizophrenia disease course. With increments in sample size and hazard ratio, we compared the performance of WTA to KM estimation and the generalized estimating equation (GEE). WTA generally required half the sample size to achieve comparable power to KM estimation; advantages over the GEE included its robust nonparametric approach and summary plot. We also applied WTA to real clinical data: the toxicity outcomes of melanoma patients receiving immunotherapy and the disease progression of patients with metastatic breast cancer receiving ramucirumab. The application of WTA demonstrated that using traditional methods such as KM estimation can lead to both type I and II errors by failing to model illness trajectory. This article outlines a novel method for clinical outcome assessment that extends the advantages of Kaplan–Meier estimates to ordinal outcome variables.

11 July 2024 in BioMedInformatics
Verified
Journal Article
Open access
PDF file
UCUtkarsh Chauhan
Utkarsh Chauhan
DMDaylen Mackey
Daylen Mackey
JMJohn Robert Mackey
John Robert Mackey
(1) Background: As Kaplan–Meier (KM) analysis is limited to single unidirectional endpoints, most advanced cancer randomized clinical trials (RCTs) are powered for either progression-free survival (PFS) or overall survival (OS). This discards efficacy information carried by partial responses, complete responses, and stable disease that frequently precede progressive disease and death. Chauhan Weighted Trajectory Analysis (CWTA) is a generalization of KM that simultaneously assesses multiple rank-ordered endpoints. We hypothesized that CWTA could use this efficacy information to reduce sample size requirements and expedite efficacy signals in advanced cancer trials. (2) Methods: We performed 100-fold and 1000-fold simulations of solid tumor systemic therapy RCTs with health statuses rank-ordered from complete response (Stage 0) to death (Stage 4). At increments of the sample size and hazard ratio, we compared KM PFS and OS with CWTA for (i) sample size requirements to achieve a power of 0.8 and (ii) the time to first significant efficacy signal. (3) Results: CWTA consistently demonstrated greater power, and it reduced the sample size requirements by 18% to 35% compared to KM PFS and 14% to 20% compared to KM OS. CWTA also expedited time-to-efficacy signals by 2- to 6-fold. (4) Conclusions: CWTA, by incorporating all efficacy signals in the cancer treatment trajectory, provides a clinically relevant reduction in the required sample size and meaningfully expedites the efficacy signals of cancer treatments compared to KM PFS and KM OS. Using CWTA rather than KM as the primary trial outcome has the potential to meaningfully reduce the numbers of patients, trial duration, and costs to evaluate therapies in advanced cancer.

13 April 2022 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
UCUtkarsh Chauhan
Utkarsh Chauhan
AGAnukul Ghimire
Anukul Ghimire
MRMilan Raval
Milan Raval
CBCurtiss Boyington
Curtiss Boyington
AHAdrienne Haponiuk
Adrienne Haponiuk
EYElaine Yacyshyn
Elaine Yacyshyn
Tetanus is extremely rare in developed countries. We report the first documented case of tetanus in the province of Alberta since 2016: a farmer that developed trismus, shoulder stiffness, and fevers eight days following orthopedic surgery. Tetanus immunoglobulin elicited rapid recovery. We highlight risk factors, pathogenesis, epidemiology, and diagnostic challenges.

7 April 2025 in Pharmaceutical Statistics
Verified
Journal Article
Open access
UCUtkarsh Chauhan
Utkarsh Chauhan
DMDaylen Mackey
Daylen Mackey
JMJohn Robert Mackey
John Robert Mackey
Analyzing and effectively communicating the efficacy and toxicity of treatment is the fundamental basis of risk–benefit analysis (RBA). There is a need for more efficient and objective tools. We apply Chauhan Weighted Trajectory Analysis (CWTA) to perform RBA with superior objectivity, power, and ease of communication. We used CWTA to perform 1000‐fold simulations of RCTs using ordinal endpoints that captured both treatment efficacy and treatment toxicity. RCTs were stochastically generated with 1:1 allocation at defined sample sizes and hazard ratios. We first studied the simplest case simulation of 3 levels each of toxicity and efficacy (a 3 × 3 matrix). We then simulated the general case of the advanced cancer trial, with efficacy graded by five RECIST 1.1 health statuses and toxicity graded by the six‐point CTCAE scale to create a 6 × 5 matrix. Finally, the 6 × 5 matrix model was applied to a real‐world dose escalation phase I trial in advanced cancer. Simulations in both the 3 × 3 simplest case matrix and the 6 × 5 advanced cancer matrix confirmed our hypothesis that drugs with both superior efficacy and toxicity profiles synergize for greater statistical power with CWTA RBA than either signal alone. The CWTA RBA 6 × 5 matrix meaningfully reduced sample size requirements over CWTA efficacy‐only analysis. Despite a small sample size, application of the matrix to each of the seven cohorts of the dose finding phase I clinical trial provided objective and statistically significant validation for the dose subjectively selected by the trialists. CWTA RBA, by incorporating both drug efficacy and the trajectory of drug toxicity, provides a single test statistic and summary plot that analyzes, visualizes, and effectively communicates the risk–benefit assessment of a clinical trial. CWTA RBA requires fewer patients than CWTA efficacy‐only analysis when the experimental drug is both more effective and less toxic. Our results show CWTA RBA has the potential to aid the objective and efficient assessment of new therapies throughout the drug development pathway. Furthermore, its distinct advantages over competing tests in visualizing and communicating risk–benefit will assist regulatory review, clinical adoption, and understanding of therapeutic risks and benefits by clinicians and patients alike.